Endoscopic treatments for obesity: Past, present and future

Christopher J. Gostout, Elizabeth Rajan

Research output: Contribution to journalReview article

15 Citations (Scopus)

Abstract

Obesity is recognized as a serious, chronic illness affecting all ages. The cause for obesity is multi-factorial, which makes successful management complex and challenging. Meaningful weight loss is frequently difficult to achieve, particularly when the goal is not merely to lose weight but to maintain this loss. The efficacy of future endoscopic approaches needs to be validated through well-designed controlled studies, and verification of safety is essential. Endoluminal therapies must have a sound physiologic basis for their development. The availability of specialized radionuclide imaging of gastric capacity and accommodation provide a useful tool in constructing interventions. Endotherapy is likely best suited for nonmorbid obese individuals with BMI ranging from 30 to 39 or as a budge to bariatric surgery. This specific BMI range has been targeted by the National Institutes of Health for emerging technologies. Presurgical weight loss to reduce surgical risk is another potential target group. Regardless of which endoscopic methods prevail, patients will continue to require a comprehensive, multi-modality management approach to this complex disease.

Original languageEnglish (US)
Pages (from-to)143-150
Number of pages8
JournalGastroenterology Clinics of North America
Volume34
Issue number1
DOIs
StatePublished - Mar 2005

Fingerprint

Weight Loss
Obesity
Biomedical Technology
Bariatric Surgery
National Institutes of Health (U.S.)
Radionuclide Imaging
Stomach
Chronic Disease
Safety
Weights and Measures
Therapeutics

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Endoscopic treatments for obesity : Past, present and future. / Gostout, Christopher J.; Rajan, Elizabeth.

In: Gastroenterology Clinics of North America, Vol. 34, No. 1, 03.2005, p. 143-150.

Research output: Contribution to journalReview article

Gostout, Christopher J. ; Rajan, Elizabeth. / Endoscopic treatments for obesity : Past, present and future. In: Gastroenterology Clinics of North America. 2005 ; Vol. 34, No. 1. pp. 143-150.
@article{8481a7e122254371b43a38e322f33929,
title = "Endoscopic treatments for obesity: Past, present and future",
abstract = "Obesity is recognized as a serious, chronic illness affecting all ages. The cause for obesity is multi-factorial, which makes successful management complex and challenging. Meaningful weight loss is frequently difficult to achieve, particularly when the goal is not merely to lose weight but to maintain this loss. The efficacy of future endoscopic approaches needs to be validated through well-designed controlled studies, and verification of safety is essential. Endoluminal therapies must have a sound physiologic basis for their development. The availability of specialized radionuclide imaging of gastric capacity and accommodation provide a useful tool in constructing interventions. Endotherapy is likely best suited for nonmorbid obese individuals with BMI ranging from 30 to 39 or as a budge to bariatric surgery. This specific BMI range has been targeted by the National Institutes of Health for emerging technologies. Presurgical weight loss to reduce surgical risk is another potential target group. Regardless of which endoscopic methods prevail, patients will continue to require a comprehensive, multi-modality management approach to this complex disease.",
author = "Gostout, {Christopher J.} and Elizabeth Rajan",
year = "2005",
month = "3",
doi = "10.1016/j.gtc.2004.12.001",
language = "English (US)",
volume = "34",
pages = "143--150",
journal = "Gastroenterology Clinics of North America",
issn = "0889-8553",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - Endoscopic treatments for obesity

T2 - Past, present and future

AU - Gostout, Christopher J.

AU - Rajan, Elizabeth

PY - 2005/3

Y1 - 2005/3

N2 - Obesity is recognized as a serious, chronic illness affecting all ages. The cause for obesity is multi-factorial, which makes successful management complex and challenging. Meaningful weight loss is frequently difficult to achieve, particularly when the goal is not merely to lose weight but to maintain this loss. The efficacy of future endoscopic approaches needs to be validated through well-designed controlled studies, and verification of safety is essential. Endoluminal therapies must have a sound physiologic basis for their development. The availability of specialized radionuclide imaging of gastric capacity and accommodation provide a useful tool in constructing interventions. Endotherapy is likely best suited for nonmorbid obese individuals with BMI ranging from 30 to 39 or as a budge to bariatric surgery. This specific BMI range has been targeted by the National Institutes of Health for emerging technologies. Presurgical weight loss to reduce surgical risk is another potential target group. Regardless of which endoscopic methods prevail, patients will continue to require a comprehensive, multi-modality management approach to this complex disease.

AB - Obesity is recognized as a serious, chronic illness affecting all ages. The cause for obesity is multi-factorial, which makes successful management complex and challenging. Meaningful weight loss is frequently difficult to achieve, particularly when the goal is not merely to lose weight but to maintain this loss. The efficacy of future endoscopic approaches needs to be validated through well-designed controlled studies, and verification of safety is essential. Endoluminal therapies must have a sound physiologic basis for their development. The availability of specialized radionuclide imaging of gastric capacity and accommodation provide a useful tool in constructing interventions. Endotherapy is likely best suited for nonmorbid obese individuals with BMI ranging from 30 to 39 or as a budge to bariatric surgery. This specific BMI range has been targeted by the National Institutes of Health for emerging technologies. Presurgical weight loss to reduce surgical risk is another potential target group. Regardless of which endoscopic methods prevail, patients will continue to require a comprehensive, multi-modality management approach to this complex disease.

UR - http://www.scopus.com/inward/record.url?scp=16844363970&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=16844363970&partnerID=8YFLogxK

U2 - 10.1016/j.gtc.2004.12.001

DO - 10.1016/j.gtc.2004.12.001

M3 - Review article

C2 - 15823444

AN - SCOPUS:16844363970

VL - 34

SP - 143

EP - 150

JO - Gastroenterology Clinics of North America

JF - Gastroenterology Clinics of North America

SN - 0889-8553

IS - 1

ER -